Abstract:Objectives Multinational R&D pharmaceutical companies operating in many countries and regions have deep ties with patient groups that are recipients of their corporate social responsibility (CSR). CSR activities are diverse and range from direct funding (including donations and sponsorships) to indirect funding (such as expenses associated with company-sponsored lectures); there are rewards for CSR requests for patient groups (writing, supervision, and surveys), and labor is provided by company employees. In developing pharmaceutical products, R&D companies can provide greater benefits to patients by listening to them. It is therefore important for all stakeholders to ensure transparency regarding the relationship between companies and patient groups. This study aimed to identify trends in information disclosure toward ensuring transparency of relations between CSR activities and patient groups based on industry groups regulations in Japan, the United States, and Europe.Methods The contents described in regulations by the European Federation of Pharmaceutical Industries and Associations (EFPIA), Pharmaceutical Research and Manufacturers of America (PhRMA), and the Japan Pharmaceutical Manufacturers Association (JPMA) concerning such transparency were qualitatively and inductively analyzed in terms of four concepts: transparency, equal partnership, mutual benefit, and independence.Results Most of the descriptions relate to transparency. The EFPIA regulation is the most detailed; it states that there should be no influence on patient groups' work or on events and activities organized by companies or patient groups. The rules of the three associations also impose the need to maintain records concerning the purpose and contents of financial support and activity items. However, information disclosure to secure transparency is not required in the PhRMA regulation. The JPMA regulation does not specify a clear update schedule; the EFPIA regulation requires disclosure information to be updated once a year. In terms of equal partnership, such terms as "mutual respect," "equal value," and "establishing a trust relationship" appeared in searches with all three regulations. None of the regulations referred to "mutual benefit." All the regulations either respected or validated the independence of patient groups.Conclusion Each pharmaceutical association set its own regulations and recommended voluntary information disclosure by member companies; however, the extent of such disclosure differed with each association. The regulations of industry associations form the basis for the policies of member companies; thus, it is desirable that the contents and regulations related to mutual information disclosure be established in great detail worldwide.

Financial Relationships Between Pharmaceutical Companies and Internal Medicine Societies

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Japanese physicians' perceptions of conflicts of interest with pharmaceutical companies: Estimating two different questioning approaches

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency

Cross-sectional analysis of pharmaceutical industry payments to authors of clinical practice guidelines for bipolar disorder and major depressive disorder in Japan

Public database on pharmaceutical ties in Japan: Traffic and user attitudes on industry-professional relationships.

Pharmaceutical company payments to Japanese breast cancer practice guideline authors

Financial conflicts of interest between infectious diseases clinical practice guideline authors and the pharmaceutical industry in Japan

Increasing trends of pharmaceutical payments to breast cancer specialists in Japan: A retrospective study from 2016 to 2019

Medical students' attitudes toward interactions with the pharmaceutical industry: a national survey in Japan

Discrepancies in Conflict-of-Interest Disclosures Among Physicians Receiving Compensation for Monoclonal Antibody Drugs

[Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States]

Supplier-Induced Demand for Chronic Disease Care in Japan: Multilevel Analysis of the Association between Physician Density and Physician-Patient Encounter Frequency

Pharmaceutical industry payments to healthcare professional organisations in the United Kingdom: a seven-year cross-sectional analysis of the Disclosure UK database from 2015 to 2021

Accuracy of post-publication Financial Conflict of Interest corrections in medical research: A secondary analysis of pharmaceutical company payments to the authors of the CREATE-X trial report in the New England Journal of Medicine

Unveiling, Analyzing the Mechanisms of, and Proposing Solutions for Bribery in Japan's Medical Device Sector

Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021

Industry Payments to US Physicians by Specialty and Product Type

Extent of physician-pharmaceutical industry interactions in low- and middle-income countries: a systematic review

Association of Compensation From the Surgical and Medical Device Industry to Physicians and Self-declared Conflict of Interest

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database